Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GAPDH | P04406 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668595 | 1.00 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL25873876 | 1.00 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24878603 | 1.00 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL26535891 | 1.00 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2258922 | 0.98 | TYMP (0.43) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL31588239 | 0.96 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL17861065 | 0.95 | TYMP (0.42) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL24829612 | 0.94 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL23668111 | 0.94 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL21073914 | 0.94 | TYMP (0.41) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002524-A1 | CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE | CureVac SE (DE) | 2025-01-02 | — | — | US | disclosed |
| WO-2024222686-A1 | RNAI AGENT FOR INHIBITING EXPRESSION OF LPA AND USE OF RNAI AGENT | 上海京新生物医药有限公司 | 2024-10-31 | — | — | WO | disclosed |
| US-12043673-B2 | Complementary RNA linked bispecific T-cell engaging antibodies | CITY OF HOPE (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240092821-A1 | SYNTHESIS OF OLIGONUCLEOTIDES AND RELATED COMPOUNDS | Janssen Biopharma, Inc. | 2024-03-21 | — | — | US | disclosed |
| CN-115843299-A | Synthesis of oligonucleotides and related compounds | 詹森生物制药有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20230092615-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSING OF METHYLATION-CONTROLLED J-PROTEIN (MCJ) | MITOTHERAPEUTIX LLC | 2023-03-23 | — | — | US | disclosed |
| EP-4126894-A1 | SYNTHESIS OF OLIGONUCLEOTIDES AND RELATED COMPOUNDS | Janssen BioPharma, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4107267-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF METHYLATION-CONTROLLED J-PROTEIN (MCJ) | Mitotherapeutix LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220175934-A1 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | MITOTHERAPEUTIX LLC | 2022-06-09 | — | — | US | disclosed |
| US-20220119552-A1 | COMPLEMENTARY RNA LINKED BISPECIFIC T-CELL ENGAGING ANTIBODIES | CITY OF HOPE | 2022-04-21 | — | — | US | disclosed |
| CN-114206389-A | Multivalent ligand clusters for targeted delivery of therapeutic agents | 有丝分裂疗法有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119552-A1 | COMPLEMENTARY RNA LINKED BISPECIFIC T-CELL ENGAGING ANTIBODIES | MCTS1, CD4, CD2 | TYMP 615/4885PRMT6 3730/4885PRKAG1 2868/4885 |
| US-12043673-B2 | Complementary RNA linked bispecific T-cell engaging antibodies | MCTS1, CD4, CD2 | TYMP 615/4885PRMT6 3730/4885PRKAG1 2868/4885 |
| US-20220175934-A1 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | ATIC, PCNA, FOLR1 | TYMP 240/4885PRMT6 4102/4885PRKAG1 4084/4885 |
| US-20250002524-A1 | CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE | RNMT, RNGTT, TRDMT1 | TYMP 97/4885PRMT6 1303/4885PRKAG1 939/4885 |
| US-20230092615-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSING OF METHYLATION-CONTROLLED J-PROTEIN (MCJ) | NSUN2, DNAJB11, DNAJB12 | TYMP 1793/4885PRMT6 596/4885PRKAG1 222/4885 |
| US-20240092821-A1 | SYNTHESIS OF OLIGONUCLEOTIDES AND RELATED COMPOUNDS | RNGTT, DCLRE1B, ADAR | TYMP 16/4885PRMT6 2252/4885PRKAG1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.